Skip to main content
OpenTrials

Clinical trial condition

Skin Diseases

Explore clinical trials studying Skin Diseases. Study availability and eligibility vary by location and protocol.

23,025 public trials 3,714 recruiting studies
Refine in advanced search Browse all conditions

Skin Diseases trial results

Recruiting

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966

Conditions
Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +10 more
Locations
  • Lucile Packard Children's Hospital Palo Alto, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago - Department of Dermatology Chicago, Illinois, United States
  • University of Texas Medical Branch Galveston, Texas, United States
View Trial Details
Recruiting

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

NCT07701590

Conditions
Cardiovascular Diseases, Diabetes Complications, Diabetes Mellitus, +16 more
Locations
  • North Park Podiatry San Diego, California, United States
  • Solutions Medical Research Coral Gables, Florida, United States
  • NAR Medical and Research Miami, Florida, United States
  • Nova Medical Services - Research Division LLC Miami, Florida, United States
View Trial Details
Recruiting

Sodium in the Skin and Atopic Dermatitis

NCT06998446

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
Locations
  • San Francisco VA Medical Center San Francisco, California, United States
  • UCSF Mt Zion Campus San Francisco, California, United States
View Trial Details
Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT07137416

Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Diseases, +24 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details

Related conditions